DENTAL-MONITORING
24.3.2020 18:50:12 CET | Business Wire | Press release
Dental Monitoring announced last week the launch of a simplified version of SmileMate Virtual Consultation - its tele dentistry solution to allow dental professionals to assess their new patient enquiries remotely and in a HIPAA compliant manner.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20200324005658/en/
Given the scale of the pandemic, and the increasing containment measures taken by governments worldwide, tele dentistry such as SmileMate Virtual Consultation has emerged as a solution to help assess patients remotely in these unprecedented times - initiating a first consultation from home and preventing the spread of COVID-19.
Standing alongside all dental professionals, Dental Monitoring has now decided to provide until the end of May 2020, free access for SmileMate Virtual Consultation to all individual dentists and orthodontists worldwide.
SmileMate Virtual Consultation is a “light” version of SmileMate, simpler and more immediate to implement for these times - enabling rapid on-boarding and roll-out. It has been developed to allow practices to remotely assess their new patients directly through their website.
CEO and Co-founder of Dental Monitoring, Philippe Salah, explained: “Allowing free access to our solution until the end of May is our duty as global citizens. It is important that we help dental professionals find solutions so they can keep providing their expert care, even during the pandemic .”
On the accelerated development of SmileMate Virtual Consultation, CEO and Founder of SmileMate, Nick Duncan said: “I think I speak for the entire dental industry when I say that our sole focus at this time is to do whatever we can to help clinics get through the current period of uncertainty. We've worked hard to develop a new version of our technology that is easier to implement for both patients and individual clinics. As a partner of dental professionals, making it free for all independent dentists and orthodontists was the right thing to do.”
Dental Monitoring is working with dental professionals, to improve its solutions and help patients access dental care anytime, anywhere.
About SmileMate Virtual Consultation
, remote assessment of new patients.
All new patient calls can be pre-qualified remotely using the SmileMate Virtual Consultation assessment tool directly through the doctor’s practice website. The process is simple:
Step 1 - The doctor simply installs a widget on its practice website. The new patient clicks on the widget, creates a profile and takes five intra-oral pictures on their smartphone (no need to download an App or use a ScanBox and cheek retractors)
Step 2 - A comprehensive customized report is automatically generated by our AI engine and sent to the doctor
Step 3 - The doctor qualifies the patient’s needs on their SmileMate portal
Step 4 - The doctor reviews and personalizes the report before sharing with the patient together with their treatment options and a booking link if an appointment is required.
To implement SmileMate Virtual Consultation, please visit: https://dental-monitoring.com/maintain-patient-care/
After May 31st, 2020, and until the end of the pandemic, SmileMate Virtual Consultation will be available at a reduced 50% cost: US$150/month.
About Fast-Track Accelerated On-Boarding
SmileMate Virtual Consultation is ready for use in minutes after doctors and their teams have performed our free fast-track accelerated onboarding - a new simplified and streamlined implementation process, which is done 100% remotely through webinars and individual support by our customer support team.
To book a time slot for our next training session, please visit: https://dental-monitoring.com/maintain-patient-care/
About Dental Monitoring
(www.dental-monitoring.com
)
Founded in 2015 by Philippe Salah, Dental Monitoring is the first AI-based company addressing the dental market. The DM software suite is designed to address the needs of dental professionals all along the patient journey: before treatment to increase the patient’s engagement, during treatment to improve the quality of care provided by the dental professionals, and after treatment to ensure the stability of the treatment outcome. The company operates in Europe, the United States and Asia-Pacific. It employs around 250 employees across its five offices located in Paris, Austin, London, Hong Kong and Sydney. SmileMate is a subsidiary of Dental Monitoring (https://www.smilemate.com/
).
View source version on businesswire.com: https://www.businesswire.com/news/home/20200324005658/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Incyte Announces New Positive 54-Week Late-Breaking Data for Povorcitinib in Hidradenitis Suppurativa at the 2026 American Academy of Dermatology (AAD) Annual Meeting28.3.2026 20:00:00 CET | Press release
Phase 3 data from the STOP-HS program demonstrate povorcitinib’s substantial and durable clinical efficacy through Week 54 in patients with moderate to severe hidradenitis suppurativa (HS). Through Week 54, clinically meaningful and durable responses were observed across all groups in both STOP-HS1 and STOP-HS2, with up to 71.4% of patients achieving HiSCR50. Improvements in clinical responses across high stringent thresholds were observed, with up to 57% of participants achieving HiSCR75 and up to 29% of participants achieving HiSCR100. Povorcitinib treatment led to consistent reductions across key inflammatory lesion types, with full resolution (ANdT=0) achieved in up to 20% of patients. Additionally, clinically meaningful improvements in quality-of-life measures, including skin pain and fatigue, were observed at Week 54. The overall safety profile of povorcitinib through 54 weeks is consistent with previously reported data, and both doses were well tolerated. Incyte (Nasdaq:INCY) to
Takeda’s Zasocitinib Delivered Rapid and Durable Skin Clearance in a Convenient Once-Daily Pill, Affirming Promise to Reshape Psoriasis Care28.3.2026 20:00:00 CET | Press release
About 70% of patients treated with zasocitinib achieved clear or almost clear skin (sPGA 0/1) at week 16 in Phase 3 plaque psoriasis studies A significantly greater PASI 75 response rate versus placebo was observed as early as week 4 Safety profile consistent with Phase 2b studies with no new safety signals identified Takeda(TSE:4502/NYSE:TAK)today announced new data from the two pivotal Phase 3studies of zasocitinib (TAK-279), a next-generation, highly selective oral tyrosine kinase 2 (TYK2) inhibitor, in adults with moderate-to-severe plaque psoriasis (PsO).1 Presented as a late-breaking abstract at the 2026 American Academy of Dermatology (AAD) Annual Meeting, these data show that convenient once-daily oral zasocitinib demonstrated rapid and durable skin clearance with a safety profile consistent with Phase 2b studies.1,2 “Our goal in psoriasis treatment is clear or almost clear skin, and previously this has been achieved primarily with injectable therapies,” said Melinda Gooderham,
AAD 2026: Late-Breaking Nemolizumab Data Demonstrate Clinically Meaningful Benefits for Children Aged 2 to 11 With Moderate-to-Severe Atopic Dermatitis28.3.2026 16:00:00 CET | Press release
Pharmacokinetics, safety and efficacy clinical study data show that nemolizumab achieved clinically meaningful reductions in skin lesions and itch through Week 16, which were sustained up to a year in children aged 2 to 11 with moderate-to-severe atopic dermatitis1 These findings reinforce the previously established safety and efficacy of nemolizumab in adults and adolescents with moderate-to-severe atopic dermatitis, for which it is approved by multiple global regulatory authorities2,3 Up to 25% of children are affected by atopic dermatitis, and currently there are limited approved treatment options for children living with moderate-to-severe atopic dermatitis4,5 Galderma (SIX: GALD) today announced new phase II data showing that nemolizumab was well tolerated and effective in children (aged 2 to 11 years) with moderate-to-severe atopic dermatitis, with a clinically meaningful and sustained reduction in skin lesions and itch for up to a year.1 Results will be presented in a late-break
Angelalign Technology (6699.HK)Releases 2025 Results: Passion for Clinical Excellence Drives Worldwide Growth27.3.2026 20:56:00 CET | Press release
Angelalign Technology Inc. (6699.HK) (“Angel” or the “Company”) released its financial results for fiscal year 2025. During the reporting period, the Company continued to do well in both the global and China markets. Total case volume was 532,400, which increased 48.1%, revenue was USD 370.3 million, which increased 37.8%, and adjusted net profit was USD 43.8 million, which increased 63.0%. The results were driven by Angel’s passion for clinical excellence and its open and inclusive culture that empowers talented people to work together to meet customer needs, the Company said. Fox Hu, CEO of Angel, stated: “The clear aligner industry is complex and multidisciplinary. It requires top-tier technical and operational talent along with seamless collaboration among professionals from diverse geographies. Angel’s open and inclusive culture attracts professionals who share a passion for clinical excellence and a dedication to bringing outstanding products and services to customers. This melti
Axway Positioned as a Leader in the IDC MarketScape: Worldwide API Management 2026 Vendor Assessment27.3.2026 18:46:00 CET | Press release
Axway, a 74Software company (Euronext: 74SW) and global leader in federated API management and enterprise integration, has been named a Leader in the IDC MarketScape: Worldwide API Management 2026 Vendor Assessment.1 Axway Amplify securely connects, orchestrates, and automates data integration. Organizations in financial services, manufacturing, healthcare, and other industries rely on Amplify to modernize integrations and confidently unlock data to deliver superior digital services faster. The report notes: “The platform benefits from Axway’s long-standing experience in B2B integration, secure file transfer, and legacy connectivity, providing differentiated capabilities for organizations that need to expose and control APIs around core systems that are not cloud-native.”1 This multi-pattern expertise in security, integration, and federated governance — built during the early phases of the API-driven digital transformation — becomes especially critical as enterprises seek to govern dat
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom